Lucigen Corporation

Lucigen Corporation is a biotechnology company that specializes in providing high-quality enzymes and reagents, enhancing research efficiency in molecular biology, particularly in DNA and RNA synthesis. Lucigen Corporation was founded in 1998 and is headquartered in Middleton, Wisconsin, US. The company develops specialized products for molecular biology applications. It was acquired by LGC Limited, a portfolio company of KKR, in February 2018.

David Mead is the founder of Lucigen, who has a history of involvement in biotechnological innovations. Lucigen, a division of LGC Biosearch Technologies, provides a diverse range of high-quality products and services to enhance life sciences research. The company specializes in developing and supplying enzymes and reagents critical for molecular biology, especially in DNA and RNA synthesis. Its key products include the QuickExtract DNA Extraction Solution, EZ-Tn5 Transposase, NxGen T7 RNA Polymerase, CircLigase ssDNA Ligase, and Ribonuclease R (RNase R).

These products support genetic research and testing, serving various clients, including academic institutions, research laboratories, and biotechnology companies across North America, Europe, and Asia. Lucigen's revenue model is based on direct sales of its specialized enzymes and reagents to research and academic institutions and biotechnology firms. Sales are made through one-time purchases or repeat orders, facilitated by Lucigen’s online ordering system. Products like the EZ-Tn5 Transposase and QuickExtract DNA Extraction Solution are essential to its revenue, fostering repeat customers due to their reliability.

Pricing is tailored to meet product specifications and client needs, with options for bulk orders and institutional partnerships, reinforcing Lucigen's market presence among life science professionals. Looking ahead, Lucigen Corporation aims to introduce new products designed for molecular biology applications, although specific release dates are yet to be announced. The company plans to expand its market reach into additional regions across North America, Europe, and Asia, targeting a broader client base by the end of 2023. The funding from its acquisition in February 2018 will support these initiatives, allowing Lucigen to leverage its resources in product development and market expansion.